SI2790699T1 - Farmacevtska zmes z izboljšano biološko razpoložljivostjo za hidrofobno spojino z visokim tališčem - Google Patents
Farmacevtska zmes z izboljšano biološko razpoložljivostjo za hidrofobno spojino z visokim tališčemInfo
- Publication number
- SI2790699T1 SI2790699T1 SI201230958A SI201230958A SI2790699T1 SI 2790699 T1 SI2790699 T1 SI 2790699T1 SI 201230958 A SI201230958 A SI 201230958A SI 201230958 A SI201230958 A SI 201230958A SI 2790699 T1 SI2790699 T1 SI 2790699T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pharmaceutical composition
- high melting
- hydrophobic compound
- improved bioavailability
- melting hydrophobic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161569863P | 2011-12-13 | 2011-12-13 | |
PCT/EP2012/074884 WO2013087546A1 (en) | 2011-12-13 | 2012-12-10 | Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound |
EP12801538.5A EP2790699B2 (en) | 2011-12-13 | 2012-12-10 | Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2790699T1 true SI2790699T1 (sl) | 2017-06-30 |
Family
ID=47358159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201230958A SI2790699T1 (sl) | 2011-12-13 | 2012-12-10 | Farmacevtska zmes z izboljšano biološko razpoložljivostjo za hidrofobno spojino z visokim tališčem |
Country Status (15)
Country | Link |
---|---|
US (3) | US20130172375A1 (sl) |
EP (1) | EP2790699B2 (sl) |
JP (1) | JP5936705B2 (sl) |
KR (1) | KR101637793B1 (sl) |
CN (1) | CN103998037B (sl) |
BR (1) | BR112014010290B8 (sl) |
CA (1) | CA2850706C (sl) |
DK (1) | DK2790699T3 (sl) |
ES (1) | ES2627531T5 (sl) |
HU (1) | HUE034548T2 (sl) |
MX (1) | MX348654B (sl) |
PL (1) | PL2790699T5 (sl) |
RU (1) | RU2014127142A (sl) |
SI (1) | SI2790699T1 (sl) |
WO (1) | WO2013087546A1 (sl) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
CN105237530A (zh) * | 2009-04-03 | 2016-01-13 | 豪夫迈罗氏公司 | 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途 |
KR20120102669A (ko) | 2009-11-06 | 2012-09-18 | 플렉시콘, 인코퍼레이티드 | 키나제 조정을 위한 화합물 및 방법, 및 이를 위한 적응증 |
WO2012109075A1 (en) | 2011-02-07 | 2012-08-16 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
CN104640545A (zh) | 2012-08-17 | 2015-05-20 | 霍夫曼-拉罗奇有限公司 | 包括给药cobimetinib和威罗菲尼的黑色素瘤的组合疗法 |
EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
WO2015103230A1 (en) * | 2013-12-31 | 2015-07-09 | Ascendia Pharmaceuticals, Llc | Pharmaceutical compositions for poorly water-soluble compounds |
WO2015121649A1 (en) * | 2014-02-12 | 2015-08-20 | Cipla Limited | Pharmaceutical composition comprising vemurafenib |
UY36046A (es) * | 2014-03-26 | 2015-10-30 | Millennium Pharm Inc | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
CZ2015250A3 (cs) | 2015-04-14 | 2016-10-26 | Zentiva, K.S. | Amorfní formy vemurafenibu |
CN105126111A (zh) * | 2015-09-30 | 2015-12-09 | 清华大学 | 提高索拉非尼生物利用度的制剂 |
JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
PL3644970T3 (pl) * | 2017-06-30 | 2022-04-25 | Acrotech Biopharma Llc | Nowe doustne preparaty belinostatu |
TWI833710B (zh) * | 2017-10-06 | 2024-03-01 | 香港商慧源香港創新有限公司 | 高單位含量口服型紫杉烷組合物及方法 |
WO2021006267A1 (ja) * | 2019-07-08 | 2021-01-14 | グリーン・テック株式会社 | ピラゾール誘導体の塩及びピラゾール誘導体の製剤 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19539363A1 (de) * | 1995-10-23 | 1997-04-24 | Basf Ag | Verfahren zur Herstellung von festen Arzneiformen |
US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
EP1594468A2 (en) * | 2003-02-03 | 2005-11-16 | Novartis AG | Process for preparing a solid dispersion pharmaceutical product |
EP1832281A1 (en) * | 2006-03-10 | 2007-09-12 | Abbott GmbH & Co. KG | Process for producing a solid dispersion of an active ingredient |
EP1880715A1 (en) * | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
WO2009108077A2 (en) † | 2008-02-28 | 2009-09-03 | Bial - Portela & Ca., S.A. | Pharmaceutical composition for poorly soluble drugs |
WO2010104945A1 (en) * | 2009-03-11 | 2010-09-16 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases |
CN105237530A (zh) * | 2009-04-03 | 2016-01-13 | 豪夫迈罗氏公司 | 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途 |
WO2011119984A1 (en) * | 2010-03-25 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide |
-
2012
- 2012-12-06 US US13/706,390 patent/US20130172375A1/en not_active Abandoned
- 2012-12-10 RU RU2014127142A patent/RU2014127142A/ru not_active Application Discontinuation
- 2012-12-10 DK DK12801538.5T patent/DK2790699T3/en active
- 2012-12-10 EP EP12801538.5A patent/EP2790699B2/en active Active
- 2012-12-10 WO PCT/EP2012/074884 patent/WO2013087546A1/en active Application Filing
- 2012-12-10 PL PL12801538T patent/PL2790699T5/pl unknown
- 2012-12-10 MX MX2014006693A patent/MX348654B/es active IP Right Grant
- 2012-12-10 SI SI201230958A patent/SI2790699T1/sl unknown
- 2012-12-10 CA CA2850706A patent/CA2850706C/en active Active
- 2012-12-10 HU HUE12801538A patent/HUE034548T2/en unknown
- 2012-12-10 BR BR112014010290A patent/BR112014010290B8/pt active IP Right Grant
- 2012-12-10 ES ES12801538T patent/ES2627531T5/es active Active
- 2012-12-10 JP JP2014546435A patent/JP5936705B2/ja active Active
- 2012-12-10 CN CN201280061576.8A patent/CN103998037B/zh active Active
- 2012-12-10 KR KR1020147016267A patent/KR101637793B1/ko active IP Right Grant
-
2018
- 2018-01-16 US US15/872,822 patent/US20180369388A1/en not_active Abandoned
-
2019
- 2019-11-25 US US16/694,713 patent/US20200330600A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20200330600A1 (en) | 2020-10-22 |
RU2014127142A (ru) | 2016-02-10 |
CA2850706C (en) | 2020-05-12 |
WO2013087546A1 (en) | 2013-06-20 |
CN103998037A (zh) | 2014-08-20 |
EP2790699B2 (en) | 2020-01-01 |
ES2627531T3 (es) | 2017-07-28 |
JP5936705B2 (ja) | 2016-06-22 |
PL2790699T5 (pl) | 2020-06-29 |
BR112014010290A2 (pt) | 2017-05-02 |
KR101637793B1 (ko) | 2016-07-07 |
US20130172375A1 (en) | 2013-07-04 |
MX2014006693A (es) | 2014-07-14 |
BR112014010290B1 (pt) | 2022-11-01 |
HUE034548T2 (en) | 2018-02-28 |
EP2790699A1 (en) | 2014-10-22 |
US20180369388A1 (en) | 2018-12-27 |
ES2627531T5 (es) | 2020-07-23 |
CA2850706A1 (en) | 2013-06-20 |
EP2790699B1 (en) | 2017-04-05 |
BR112014010290B8 (pt) | 2022-11-29 |
KR20140096124A (ko) | 2014-08-04 |
JP2015500306A (ja) | 2015-01-05 |
CN103998037B (zh) | 2018-02-16 |
PL2790699T3 (pl) | 2017-08-31 |
MX348654B (es) | 2017-06-21 |
DK2790699T3 (en) | 2017-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2790699T3 (pl) | Kompozycja farmaceutyczna wysokotopliwego związku hydrofobowego o polepszonej dostępności biologicznej | |
AP3864A (en) | Pharmaceutical composition | |
HK1203514A1 (en) | -amino acid compounds for liver isease | |
PL2776416T3 (pl) | Związki farmaceutyczne | |
GB201118232D0 (en) | Pharmaceutical composition | |
AP3656A (en) | Pharmaceutical compositions | |
IL230861A (en) | A rapidly dissolving pharmaceutical composition | |
HK1182638A1 (en) | Solid pharmaceutical composition containing benzimidazole derivative | |
EP2702989A4 (en) | STABLE PHARMACEUTICAL COMPOSITION | |
ZA201307593B (en) | Antihypertensive pharmaceutical composition | |
HK1201534A1 (en) | Pharmaceutical compounds | |
HK1189158A1 (en) | Pharmaceutical composition | |
GB201119799D0 (en) | Pharmaceutical compounds | |
GB201118876D0 (en) | Pharmaceutical compounds | |
GB201113163D0 (en) | Pharmaceutical compounds | |
EP2727593A4 (en) | PHARMACEUTICAL COMPOSITION CONTAINING NICORANDIL | |
EP2711010A4 (en) | PHARMACEUTICAL COMPOSITION | |
HUP1100444A2 (en) | Pharmaceutical composition | |
ZA201308414B (en) | Solid pharmaceutical composition | |
EP2727594A4 (en) | NEW PHARMACEUTICAL COMPOSITION | |
HUP1100445A2 (en) | Pharmaceutical composition | |
EP2714715A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
GB201118875D0 (en) | Pharmaceutical compounds | |
GB201118874D0 (en) | Pharmaceutical compounds | |
GB201117359D0 (en) | Pharmaceutical compounds |